Arch Biopartners Licenses Drug Candidate to Treat CF Lung Infections
Cystic Fibrosis, News
Arch Biopartners, Inc., recently announced that it has entered an exclusive license agreement with the University of Cincinnati (UC) for commercial rights to UC’s AB569, a drug candidate for the ... Read more